Stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9724383
SERIAL NO

14796725

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NEW YORK BLOOD CENTER310 EAST 67TH STREET NEW YORK NY 10021

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Xi Elmhurst, US 903 6756
Jiang, Shibo New York, US 38 308
Pan, Chungen Guangdong Province, CN 7 20
Qi, Zhi Corona, US 6 20

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 8, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 8, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00